TONIX PHARMACEUTICALS HOLDING CORP. Accumulated Other Comprehensive Income
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Accumulated Other Comprehensive Income of -$348.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$348.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$283.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$289.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$274.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$348.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$283.00K 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$289.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$274.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$270.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$266.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$255.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$250.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$243.00K 10-Q · filed 2024-08-16 |
| 2024-03-31 | -$240.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$232.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | -$220.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$212.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$211.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$167.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$160.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$143.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$118.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$92.00K 10-K · filed 2023-03-13 |
| 2021-09-30 | -$81.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$71.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$63.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$62.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | -$64.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$69.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$60.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$46.00K 10-K · filed 2021-03-15 |
| 2019-09-30 | -$42.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$39.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | -$39.00K 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$41.00K 10-K · filed 2020-03-24 |
| 2018-09-30 | -$29.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$34.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | -$13.00K 10-Q · filed 2018-05-11 |
| 2017-12-31 | -$12.00K 10-K · filed 2019-03-18 |
| 2017-09-30 | -$10.00K 10-Q · filed 2017-11-06 |
| 2017-06-30 | -$9.00K 10-Q · filed 2017-08-11 |
| 2017-03-31 | -$8.00K 10-Q · filed 2017-05-12 |
| 2016-12-31 | -$7.00K 10-K · filed 2018-03-09 |
| 2016-09-30 | $11.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $18.00K 10-Q · filed 2016-08-05 |
| 2016-03-31 | $26.00K 10-Q · filed 2016-05-06 |
| 2015-12-31 | -$17.00K 10-K · filed 2018-03-09 |
| 2015-09-30 | $17.00K 10-Q · filed 2015-11-06 |
| 2015-06-30 | $6.00K 10-Q · filed 2015-08-07 |
| 2015-03-31 | $5.00K 10-Q · filed 2015-05-08 |
| 2014-12-31 | $2.00K 10-K · filed 2017-04-13 |
| 2014-09-30 | $1.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $4.00K 10-Q · filed 2014-08-08 |
| 2014-03-31 | $1.00K 10-Q · filed 2014-05-13 |
| 2013-12-31 | -$1.00K 10-K · filed 2015-02-27 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |